Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent GlioblastomaLakshmi Nayak, Annette M Molinaro, Katherine Peters, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2022
Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent GlioblastomaLakshmi Nayak, Nathan Standifer, Jorg Dietrich, et al.
Acta Neuropathologica Communications|June 9, 2018
The genetic landscape of gangliogliomaMelike Pekmezci, Javier E Villanueva-Meyer, Benjamin Goode, et al.
Neuro-Oncology Advances|March 7, 2025
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survivalEduardo Rodriguez Almaraz, Geno A Guerra, Nadeem N Al-Adli, et al.
Neuro-Oncology|September 27, 2023
A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomasAtsuro Saijo, Hirokazu Ogino, Nicholas A Butowski, et al.
The Journal of Clinical Investigation|December 9, 2021
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomasHirokazu Ogino, Jennie W Taylor, Takahide Nejo, et al.
Neuro-Oncology|April 8, 2022
Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomesYalan Zhang, Calixto-Hope G Lucas, Jacob S Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2017
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive GlioblastomaSara A Byron, Nhan L Tran, Rebecca F Halperin, et al.
Acta Neuropathologica|December 11, 2023
"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockadeSara Hadad, Rohit Gupta, Nancy Ann Oberheim Bush, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
Pageof 14